The document discusses the need for global collaboration to conquer Alzheimer's disease. It notes that knowing is not enough and we must apply what we know. It advocates changing the dialogue around Alzheimer's to focus on the disease rather than just the patient. Key needs for "disease interception" are identified, including increased investment in basic science, incentivizing innovators, improving diagnostic tools and biomarkers, establishing clinical trial registries, building translational infrastructure between registries and trial-ready cohorts, using relevant outcomes measures, and creating a synchronized regulatory environment. The presentation promotes the Global Alzheimer's Platform as a way to foster data sharing, collaboration, and building a "global connectome" to accelerate progress on Alzheimer's.

1. Brian Jackson, Untitled 6 Artwork from Reflections Art in
Health
I have been impressed with the urgency of doing.
Knowing is not enough; we must apply. Being
willing is not enough; we must do.
–Leonardo da Vinci
Luc Truyen MD PhD
VP Neuroscience External Affairs Janssen and
Chair, Global Fight against Alzheimer’s Disease, Johnson & Johnson
Program Director, Global Alzheimer’s Platform
Global Collaboration: key to
conquering Alzheimer’s Disease

2. Disclaimer
The opinions expressed in this presentation are those of the
presenter only and do not necessarily reflect the positions or
opinions of Janssen Research and Development, L.L.C. or any other
individual or affiliate of Johnson & Johnson. The presenter makes
no warranties with respect to the accuracy of the data or materials
presented herein. All information is provided for informational
purposes only and does not constitute advice regarding clinical
research-related activities.

3. Photograph by Judith Fox from I Still Do:
Loving and Living with Alzheimer's
We need to change the dialogue:
From the 70 year old patient with Alzheimer’s Dementia
To the 40 year old person with Alzheimer’s Disease

4. Key needs to get to ‘disease interception’
 Increased investment in basic science
 Incentivized innovators
 Identifying and capturing the right subjects for trials
– Clinimetrics
– Diagnostics and Biomarkers
– ‘Registries’
 Translational infrastructure
– Registries to trial ready cohorts
– Sites that are qualified and ready with access to required tech
– Effective trial designs: learn fast, confirm efficiently
 Relevant outcomes
– Surrogate markers
– Sensitive cognitive measures
– Economic impact models
 A convergent, synchronized regulatory and payor
environment

5. Global Alzheimer’s Platform
U.K.
Dementia
Platform
AIBL
COLLABORATION
DATA SHARING KNOW HOW
AMP
WW-ADNI
We need a
global
connectome

6. Thank you